- Previous Close
1,091,000.00 - Open
1,085,000.00 - Bid 1,075,000.00 x --
- Ask 1,076,000.00 x --
- Day's Range
1,067,000.00 - 1,113,000.00 - 52 Week Range
698,000.00 - 1,113,000.00 - Volume
77,390 - Avg. Volume
124,503 - Market Cap (intraday)
76.512T - Beta (5Y Monthly) 0.39
- PE Ratio (TTM)
-- - EPS (TTM)
-- - Earnings Date Oct 23, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
1,029,400.00
Samsung Biologics Co.,Ltd. engages in the contract development and manufacturing organization (CDMO) business for biopharmaceuticals products in South Korea, Europe, the United States, and internationally. The company operates in two segments, CDMO, and Biopharmaceutical Development and Commercialization. Its development services include discovery, cell line development, process development, and clinical manufacturing. The company also offers aseptic filling, lyophilization, finishing, storage and shipping, and support services; and quality assurance and control, as well as biosafety and analytical testing services. In addition, it engages in the research and commercialization of biosimilar drugs; development and manufacture of antibody-drug conjugates; and manufactures mammalian and mRNA products. The company was founded in 2011 and is headquartered in Incheon, South Korea.
samsungbiologics.comRecent News: 207940.KS
View More
Performance Overview: 207940.KS
Trailing total returns as of 10/22/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 207940.KS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 207940.KS
View MoreValuation Measures
Market Cap
77.65T
Enterprise Value
77.76T
Trailing P/E
75.50
Forward P/E
62.50
PEG Ratio (5yr expected)
3.59
Price/Sales (ttm)
18.44
Price/Book (mrq)
7.52
Enterprise Value/Revenue
18.47
Enterprise Value/EBITDA
38.60
Financial Highlights
Profitability and Income Statement
Profit Margin
24.42%
Return on Assets (ttm)
5.17%
Return on Equity (ttm)
10.47%
Revenue (ttm)
4.21T
Net Income Avi to Common (ttm)
1.03T
Diluted EPS (ttm)
--
Balance Sheet and Cash Flow
Total Cash (mrq)
1.57T
Total Debt/Equity (mrq)
16.28%
Levered Free Cash Flow (ttm)
525.97B
Research Analysis: 207940.KS
View MoreCompany Insights: 207940.KS
207940.KS does not have Company Insights